Ascendis Pharma aims for USD 400m from share issue
A week after Ascendis Pharma received approval for its once-weekly growth hormone treatment, the biotech company has started to look for capital.
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY CATHERINE BRETT
Ascendis Pharma wants to bulk up its economic muscles and has therefore started an equity issuance the company hopes can bring in USD 400m (DKK 2.5bn) to the firm.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Ascendis ready for new hires after FDA approval
For subscribers
FDA approves Ascendis' weekly growth hormone
For subscribers
Ascendis aiming to become market leader
For subscribers
.jpg&w=384&q=75)
